As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable.
Please note that following on from advice received from the company the timelines for this appraisal have been revised.
We now anticipate that the appraisal will begin during mid- March 2020 when we will write to you about how you can get involved.